Health professional

Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa 

Retrieved on: 
Wednesday, March 27, 2024
Vector, Dexamethasone, Disease, Bone marrow, Partnership, Patient, Multiple myeloma, Cancer, WODA, Health professional, PDC, Medicine, Pharmaceutical industry

Under the terms of this exclusive agreement, Vector will distribute Pepaxti to patients in the MENA region for the treatment of patients with multiple myeloma.

Key Points: 
  • Under the terms of this exclusive agreement, Vector will distribute Pepaxti to patients in the MENA region for the treatment of patients with multiple myeloma.
  • The two parties have agreed on a revenue split on all Pepaxti sales in the region, with Vector carrying all costs through their existing structure in the region.
  • “I am excited to announce this regional agreement with Oncopeptides,” says Vector Pharma FZCO Managing Partner Patrick Jordan.
  • “We are happy for our partnership with Vector and look forward to working together as we enter this promising region together.

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

Retrieved on: 
Saturday, April 6, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, Science, TEVA, De novo, Patient, Interview, NNH, Tardive dyskinesia, Congress, Medication, Risperidone, International, Risk, NNT, Caregiver, Safety, HCP, Emotion, Teva Pharmaceuticals, Health professional, Data wrangling, Death, Lais, Teva, FDA, Olanzapine, SIRS, Perception, Physician, Schizophrenia International Research Society, Persistence

The data were presented at the 2024 Congress of the Schizophrenia International Research Society (SIRS) taking place from April 3-7, 2024 in Florence, Italy.

Key Points: 
  • The data were presented at the 2024 Congress of the Schizophrenia International Research Society (SIRS) taking place from April 3-7, 2024 in Florence, Italy.
  • “Schizophrenia is a complex mental health condition where the treatment needs and preferences of those living with it may evolve over time.
  • In the patient survey, approximately 20 patients and 19 caregivers completed a 60-minute interview regarding the use of LAIs in schizophrenia.
  • Below is the full set of data presented by Teva at SIRS 2024.

United States Dermatology KOLs Fair-Market Value Compensation Rate Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 13, 2024
Professional Services, Health, Thought Leadership, Practice Management, Other Health, General Health, Biotechnology, Physician, Dermatology, Perception, Research, KOL, Health professional, Insurance

The "Fair-Market Value Compensation Rates for Dermatology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fair-Market Value Compensation Rates for Dermatology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.
  • KOL FMV Rates Dermatology USA presents fair-market value compensation rates for US-based Dermatology KOLs, by percentiles, with averages, for four (4) levels of Thought Leader influences (rare, international, national, and local).
  • These defensible market-based rate data are built directly from industry compensation paid to Healthcare Practitioners (HCPs) and Thought Leaders (KOLs).
  • Establishing fair-market value compensation rates will:
    Reduce the external perception of inappropriate inducement and limit regulatory and compliance risks.

United States Neurology KOLs Fair-Market Value Compensation Rate Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 13, 2024
Professional Services, Health, Neurology, Thought Leadership, Physician, Perception, Research, KOL, Health professional, Insurance

The "Fair-Market Value Compensation Rates for Neurology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fair-Market Value Compensation Rates for Neurology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.
  • Thought Leader Compensation US Neurology presents fair-market value compensation rates for US-based KOLs in neurology, by percentiles, with averages, for four (4) levels of Thought Leader influences (rare, international, national, and local).
  • These defensible market-based rate data are built directly from industry compensation paid to Healthcare Practitioners (HCPs) and Thought Leaders (KOLs).
  • Establishing fair-market value compensation rates will:
    Reduce the external perception of inappropriate inducement and limit regulatory and compliance risks.

Olympus Announces FDA Clearance of RenaFlex™, Its First Single-use Flexible Ureteroscope

Retrieved on: 
Tuesday, April 2, 2024
System, U.S. FDA, Burns, Urology, Small Business Saturday, Lithotripsy, Endoscopy, Risk, Patient, Perforation, Infection, Health professional, Bleeding, Ureteroscopy, Kidney, Ureter, Urethra, Physician, Medical imaging

CENTER VALLEY, Pa., April 2, 2024 /PRNewswire/ -- Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today U.S. FDA 510(k) clearance of its first single-use ureteroscope system, RenaFlex™, with full market availability to be announced at a later date.

Key Points: 
  • The RenaFlex single-use flexible ureteroscope system is used to access and visualize the urinary tract to diagnose and treat urinary diseases and disorders, such as kidney stones.
  • The RenaFlex ureteroscope can be used with endotherapeutic accessories to perform diagnostic and therapeutic procedures within the urinary tract.
  • The RenaFlex Single-use Ureteroscope works in combination with the compatible CV-S1 Video System Center for flexible Single-use Endoscopes.
  • Visit the urology product page for more information about the complete line of Olympus urology solutions.

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Retrieved on: 
Wednesday, March 27, 2024
Community, Patient, Colostomy, Health care, Bacteria, Quality of life, Shoe, Curriculum, Western world, Abdominal pain, IBD, Immune system, Diarrhea, Disease, Health professional, Crohn's disease, Student, Environment, Caregiver, Incidence, Empathy, Abdomen, Inflammatory bowel disease, HY

DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE. The initiative, focused on raising awareness of the difficult symptoms of Inflammatory Bowel Disease (IBD), entailed an immersive 24-hour simulation that generated a deeper understanding of how the disease affects the daily lives of patients.

Key Points: 
  • DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE.
  • While inflammation is the body's natural reaction to irritation or injury, in patients with IBD, it is thought that the body's own immune system mistakenly identifies a harmless food or bacteria within the gut as 'foreign' and attacks it3.
  • Using a mobile app and an 'IBD kit,' participants engaged in common struggles, gaining insights into the disease's physical and emotional challenges.
  • Although the simulation couldn't fully replicate the experience, it is meant to foster empathy for individuals living with IBD.

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Retrieved on: 
Wednesday, March 27, 2024
Community, Patient, Colostomy, Health care, Bacteria, Quality of life, Shoe, Curriculum, Western world, Abdominal pain, IBD, Immune system, Diarrhea, Disease, Health professional, Crohn's disease, Student, Environment, Caregiver, Incidence, Empathy, Abdomen, Inflammatory bowel disease, HY

DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE. The initiative, focused on raising awareness of the difficult symptoms of Inflammatory Bowel Disease (IBD), entailed an immersive 24-hour simulation that generated a deeper understanding of how the disease affects the daily lives of patients.

Key Points: 
  • DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE.
  • While inflammation is the body's natural reaction to irritation or injury, in patients with IBD, it is thought that the body's own immune system mistakenly identifies a harmless food or bacteria within the gut as 'foreign' and attacks it3.
  • Using a mobile app and an 'IBD kit,' participants engaged in common struggles, gaining insights into the disease's physical and emotional challenges.
  • Although the simulation couldn't fully replicate the experience, it is meant to foster empathy for individuals living with IBD.

Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure

Retrieved on: 
Tuesday, March 19, 2024
CSL Vifor, University, Research, Exercise, Classification, Health professional, Risk, Patient, Public, Palpitations, Health care, NYHA, News, Periodic breathing, Cardiovascular Research, Quality of life, Health Canada, Woman, Heart failure, Anemia, Fatigue, Hospital, Dietary supplement

Research shows that rates of iron deficiency are even higher than previously reported in Canada, with the condition particularly prevalent in women of reproductive age3 and children4.

Key Points: 
  • Research shows that rates of iron deficiency are even higher than previously reported in Canada, with the condition particularly prevalent in women of reproductive age3 and children4.
  • "The news of a new treatment option tested in clinical trials is welcomed, given that oral irons may not be able to adequately deliver the desired outcomes for Canadian patients with heart failure impacted by iron deficiency."
  • Iron deficiency affects one in every two hospitalized patients with heart failure5.
  • * The New York Heart Association Functional Classification is used by Healthcare Professionals to classify patients' heart failure based on the severity of their symptoms.

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting, European Medicines Agency, Amsterdam, the Netherlands, 3 July 2024

Retrieved on: 
Wednesday, April 3, 2024
Health professional, Consumer, European Medicines Agency, PCWP, Party, Health care, Patient, EMA

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting

Key Points: 

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting
This meeting brings together the members of the Patients and Consumers Working Party (PCWP) and the Healthcare Professionals Working Party (HCPWP).
EventHuman

Avicanna Hosts Symposium on Cannabinoid-based Medicine  

Retrieved on: 
Thursday, February 29, 2024
Education, Health professional, Patient

Avicanna’s team will also be presenting advancements in cannabinoid-based research including the Company’s recently completed research studies in addition to introducing to the MyMedi.ca medical cannabis care platform.

Key Points: 
  • Avicanna’s team will also be presenting advancements in cannabinoid-based research including the Company’s recently completed research studies in addition to introducing to the MyMedi.ca medical cannabis care platform.
  • “We feel privileged to bring together clinicians and thought leaders with direct experience in prescribing cannabinoid-based medicine and medical cannabis to patients.
  • Our aim is to increase discussion and further explore possibilities around cannabinoid-based medicine’s potential as a treatment option for HCPs” stated Dr. Karolina Urban, Executive Vice President of Medical Affairs at Avicanna.
  • To register for the symposium:
    Health care practitioners and researchers, may apply for registration at: www.avicanna.com/symposium